

## SUPPLEMENTARY MATERIALS

Onabajo, Banday et al,

### Supplementary Tables

**Table S1.** Expression of IFNs and select ISGs in T47D cells at baseline and after SeV infection, RNA-seq FPKM, hg38

Gene	IFN type	Untreated 1	Untreated 2	SeV 12hrs.1	SeV 12hrs.2
IFNA1	Type I	0.00	0.00	0.52	0.27
IFNA2	Type I	0.00	0.00	0.13	0.04
IFNA4	Type I	0.00	0.00	0.00	0.00
IFNA5	Type I	0.00	0.00	0.00	0.00
IFNA6	Type I	0.00	0.00	0.00	0.00
IFNA7	Type I	0.00	0.00	0.30	0.25
IFNA8	Type I	0.00	0.00	0.00	0.05
IFNA10	Type I	0.00	0.00	0.24	0.39
IFNA13	Type I	0.00	0.00	0.33	0.09
IFNA14	Type I	0.00	0.00	0.00	0.08
IFNA16	Type I	0.00	0.00	0.00	0.11
IFNA17	Type I	0.00	0.00	0.00	0.00
IFNA21	Type I	0.00	0.00	0.00	0.05
<b>IFNB1</b>	<b>Type I</b>	<b>0.00</b>	<b>0.00</b>	<b>337.30</b>	<b>381.62</b>
IFNE	Type I	0.00	0.00	0.04	0.03
IFNK	Type I	0.00	0.00	0.00	0.00
IFNG	Type II	0.00	0.00	0.00	0.00
<b>IFNL1</b>	<b>Type III</b>	<b>0.00</b>	<b>0.00</b>	<b>252.53</b>	<b>292.93</b>
<b>IFNL2</b>	<b>Type III</b>	<b>0.00</b>	<b>0.00</b>	<b>110.41</b>	<b>123.48</b>
<b>IFNL3</b>	<b>Type III</b>	<b>0.00</b>	<b>0.00</b>	<b>122.21</b>	<b>138.66</b>
<b>IFNL4</b>	<b>Type III</b>	<b>0.00</b>	<b>0.00</b>	<b>122.77</b>	<b>132.11</b>
ISG15	ISG	4.29	3.25	2698.66	3206.30
IFIT1	ISG	0.94	0.81	879.53	1033.89
MX1	ISG	5.20	4.66	849.95	881.69

FPKM - fragments per kilobase of exon per million reads mapped

**Table S2. Expression of *ACE2* and *dACE2* in various cell lines and conditions** (separate Excel file)

**Table S3. Cell lines used**

<b>Cells</b>	<b>Cell type</b>	<b>Source</b>	<b>Media</b>
Primary tonsil epithelial cells	Normal tissue from donors	ScienCell	Tonsil Epithelial Cell Medium
T47D (MDA-MB-23)	Breast cancer	ATCC	DMEM
T24	Bladder cancer	ATCC	McCoy's 5A
HT-1376	Bladder cancer	ATCC	DMEM
HTB-9	Bladder cancer	ATCC	RPMI-1640
RT-4	Bladder cancer	ATCC	McCoy's 5A
HBLAK	Immortalized uroepithelial	CELLnTEC	CnT-Prime
PC3	Prostate cancer	ATCC	F-12
22RV1	Prostate cancer	ATCC	RPMI
DU145	Prostate cancer	ATCC	EMEM
HepG2	Liver cancer	ATCC	DMEM
Caco-2	Colon cancer	ATCC	EMEM
T84	Colon cancer	ATCC	DMEM: F-12
A549	Lung cancer	ATCC	F-12
Calu3	Lung cancer	ATCC	DMEM
Capan-1	Pancreatic cancer	ATCC	IMDM
HeLa	Cervical cancer	ATCC	EMEM
TCCSUP/HTB5	Bladder Cancer	ATCC	EMEM
5637/HTB9	Bladder Cancer	ATCC	RPMI
J82	Bladder Cancer	ATCC	EMEM
SW780	Bladder Cancer	ATCC	Leibovitz's L-15 Medium
UMUC3	Bladder Cancer	ATCC	EMEM
293T	Kidney	ATCC	DMEM
NHBE	Primary normal human bronchial epithelial cells from 5 donors Described in (Santer et al., 2020)	International Institute for the Advancement of Medicine	BEGM (bronchial epithelial growth medium) + bulletkit
Organoid cultures of colon and ileum	Described in (Stanifer et al., 2020)	University Hospital Heidelberg	Human organoid media

ATCC - American Type Culture Collection

**Table S4. Primers and expression assays used**

Primers	Sequence	Assay type, amplicon size
ACE2_F	GGGCGACTTCAGGATCCTTAT	ACE2 SYBR Green assay, 80 bp
ACE2_R	GGATATGCCCCATCTCATGATG	
dACE2_F	GGAAGCAGGCTGGGACAAA	dACE2 SYBR Green assay, 73 bp
dACE2_R	AGCTGTCAGGAAGTCGTCCATT	
ACE2_F	GGGCGACTTCAGGATCCTTAT	ACE2 TaqMan assay, 80 bp
ACE2_R	GGATATGCCCCATCTCATGATG	
ACE2_probe	ATGGACGACTTCCTGACAG	
dACE2_F	GGAAGCAGGCTGGGACAAA	dACE2 TaqMan assay, 73 bp
dACE2_R	AGCTGTCAGGAAGTCGTCCATT	
dACE_probe	AGGGAGGATCCTTATGTG	
dACE2_F	AGTGCTTCATTGAGGAGAGCTCT	dACE2, 5'-3'UTR, 1535 bp 98°C-30s, 98°C-10s, 60°C-30s, 72°C-40s, 35 cycles, 72°C-2 min; Q5 High-Fidelity 2X PCR Master Mix (NEB)
dACE2_R	TCTATACCATGAAATTAACATTTACATACAAC	
HPRT1_F	TGACACTGGCAAAACAATGCA	SYBR Green assay, 94 bp
HPRT1_R	GGTCCTTTTCACCAGCAAGCT	
MX1_F	ACCTGATGGCCTATCACCAG	SYBR Green assay, 154 bp
MX1_R	TTCAGGAGCCAGCTGTAGGT	
IFIT1_F	AAAAGCCCACATTTGAGGTG	SYBR Green assay
IFIT1_R	GAAATTCCTGAAACCGACCA	SYBR Green assay
GAPDH	Hs04420632_g1 (Thermo Fisher)	TaqMan assay
ACTB	4352667 (Thermo Fisher)	
ISG15	Hs01921425_s1 (Thermo Fisher)	TaqMan assay

**Table S5. Reagents used**

<b>Antibodies</b>						
<b>Target gene</b>	<b>Cat. No.</b>	<b>Source</b>	<b>Target species</b>	<b>Host</b>	<b>Tag</b>	<b>Dilution</b>
ACE2	ab15348	Abcam	Human	Rabbit		1:250
Myc-DDK		Thermo Fisher	Tag	Rabbit		1:1000
GAPDH	Ab9485	Abcam	Human	Rabbit		1:1000
GFP	MA515256	Thermo Fisher	Tag	Mouse		1:1000
DYKDDDDK Epitope Tag	NB600- 347	Novus Biologicals	Tag	Goat		1:1000
IgG	#7074	Cell Signaling	Rabbit	Goat	HRP	1:5000
IgG	sc2314	Santa Cruz	Mouse	Donkey	HRP	1:5000
IgG	sc2304	Santa Cruz	Goat	Donkey	HRP	1:5000
Streptavidin	SA10044	Thermo Fisher	Tag		PE	1:200
IgG	A32734	Thermo Fisher	Rabbit	Goat	AF680	1:200
<b>Interferons</b>						
<b>IFN</b>	<b>Source</b>		<b>Concentration</b>	<b>Time</b>	<b>Experiment</b>	
IFN $\alpha$ 2b	Merck, Intron A		100 IU/ml	24 hrs	NHBE	
IFN- $\lambda$ 3	R&D Systems, Cat# 5259-IL/CF		100 ng/ml	24 hrs	NHBE	
IFN- $\beta$ 1	Biomol, Cat#86421		2000IU/mL	24 hrs	Organoids Cell lines	
IFN- $\lambda$ 1	Peprotech, Cat#300-02L		100 ng/ml	24 hrs	Organoids Cell lines	
IFN- $\lambda$ 2	Peprotech, Cat#300-02K		100 ng/ml	24 hrs	Organoids Cell lines	
IFN- $\lambda$ 3	Biomol, Cat#179- ML-025		100 ng/ml	24 hrs	Organoids Cell lines	
IFN- $\beta$	R&D Systems, Cat# 8499-IF		0.5 ng/ml	48 hrs	Cell lines	
IFN- $\gamma$	R&D Systems Cat# 285-IF		2 ng/ml	48 hrs	Cell lines	


**Table S6. RNA-seq datasets analyzed**

Datasets	NCBI SRA	Alignment reference genome	Reference
Breast cancer cell line T47D, SeV-infected for 12 hours (n=2), not infected, n=2	PRJNA512015	hg19	Current work
Nasal epithelial cells from 30 asthmatic patients were infected with rhinovirus strains - RV-A16 (n=30), RV-C15 (n=30) or not infected (n=30)	PRJNA627860	hg38	NA
Human lung explants infected with influenza A/H3N2 virus from 5 donors, n=20	PRJNA557257	hg38	NA
Lung cells infected with the respiratory syncytial virus (RSV): human lung mucoepidermoid pulmonary carcinoma cell line H292, RSV-infected (n=1) and mock (n=1); lung cells from mice infected with RSV, n=3 and mock, n=3	PRJNA588982	hg38 and mm10	(McAllister et al., 2020)
Normal human tissues, n = 95	PRJEB4337	hg38	(Fagerberg et al., 2014)

**Table S7. Nucleotide sequences and genome coordinates of three alternative first exons of *ACE2* and *dACE2* used for quantification of RNA-seq reads**

Exon	Sequence	Coordinates, hg38	Length, bp	RefSeq ID
ACE2, Ex1a	GGCACTCATACATACTCTGGCA ATGAGGACACTGAGCTCGCTTCTG AAATTTGACAAGATAACCACTAAA ATCTCTTTGAATTCTATGTTGTTGT GATCCCATGGCTACAGAGGATCAG GAGTTGACATAGATACTCTTTGGAT TTCATACCATGTGGAGGCTTTCTTA CTTCCACGTGACCTTGACTGAGTTT TGAATAG	chrX:15,601,956- 15,602,158	203 bp	NM_021804.3
ACE2, Ex1b	CGCCCAACCCAAGTTCAAAGGCTG ATAAGAGAGAAAATCTCATGAGGA GGTTTTAGTCTAGGGAAAGTCATTC AGTGGATGTGATCTTGGCTCACAG GGGACGATGTCAAGCTCTTCCTGG CTCCTTCTCAGCCTTGTTGCTGTAA CTGCTGCTCAGTCCACCATTGAGG AACAGGCCAAGACATTTTGGACA AGTTTAACCACGAAGCCGAAGACC TGTTCTATCAAAGTTCACCTTGCTTC TTGGAATTATAACACCAATATTACT GAAGAGAATGTCCAAAACATG	chrX:15,600,726- 15,601,014	289 bp	NM_021804
dACE2, Ex1c	GTAATTCCCAGGTTGCAGGCTT GTGAGAGCCTTAGGTTGGATTC CCTAGCTTGAAAAGGAGATCGT TTTACAAGTGCTTCATTGAGGA GAGCTCTGAGGCAGAGGGGAA TGAGGGAAGCAGGCTGGGACA AAGGAGGGAG	chrX:15,580,281- 15,580,420	140 bp	MT505392


## Supplementary Figures



**Figure S1. Analysis of promoter regulatory elements relevant for IFN signaling**

Promoters of *ACE2* (P1 and P2) and *dACE2* (P3) were analyzed for binding motifs of transcription factors relevant for IFN signaling. Promoters were defined within the -800 bp/+100 bp window from the corresponding transcription start sites (TSS).

A







<b>B</b>	Human	GCTCTATGGAGAACTGGAAGAAACTGA-----CCACATTTGCAATAGGAGATAGGATC
	Mouse	-GTGTGACCAATCCTGATTTAAATCTGGCATTGGAGTGGTTCATGAGATCAGACTGGAGC
		* * * * *
	Human	AGACCGTGCTTTACAAGTGGGATTGGAATTAGGTTTGGAAAGACAAGAAGGATTTCAGATA
	Mouse	CAAATCTCTATCGCAGGTTGCATTCTTATCTGCTTTGCCTG-TCCAGAGCTGTTCCCTCA
		* * * * *
	Human	CACAGAGTCG-GGAGGAGGACCCAAGCTGTGAGAACAGCAGGATCAAATACAG-----A
	Mouse	CTTGCCTTTGTCTGAGAGGTTCTCCCTTACATAAAATCACCAGCTGAAGCCAGGGAGCA
		* * * * *
	Human	GAGGCAGGACCTGACCTGCATACTGAAGTCGGCAAGTTAGGCTAGAAT---GAGAA---
	Mouse	AACCCAAAGACACAACTTGCAACCTGGGCATTAGAGTTCTGCTTTATAAATAAGGAACT
		* * * * *
	Human	ATAAGTGAAGGAGAGTTTGTGTAATGTGGCAGAATGAGCA-----CAGGCTTCAGAATCC
	Mouse	GGAACCCAAAGATTACTTTGCTCAAGGTTGCCTGATCATTCAAGTACACACCTTGGATTCC
		* * * * *
	Human	TAGGTGTGTCACTTAATGACTATGCAACCTTGGACAAGGTATTT-----AAGTTCTTTG
	Mouse	AAAGCCT-----ATGCTCATTCTGCCACATAGCAGACTCACACTGTCCTACACATATTTT
		* * * * *
		P3 TSS dACE2-Ex1c
	Human	GTTTCAGTTTCCTTATTTTATAAAGTAGAATAGTAATTCCCAGGTTGCAGGCTTGTGAGA
	Mouse	TTGTCAATTGTTGTTCTAGTCTAAACTTGCCGGCGTCAGCACCCACACCAGG-TCC--TGA
		* * * * *
	Human	GCCTTAGGTTGGATTCCCTAGCTTGAAAAGGAGATCGTTTTACAAGTGCTTCATTGAGGA
	Mouse	TACTTCTGTTCTTCCAACCTGCTGTGCTCCAGGAGTCTGCCTAACCTCTTCTTGCAATT
		* * * * *
		5'UTR Coding
	Human	GAGCTCTGAGGCAGAGGGGAATGAGGGAAGC--AGGCTGGGACA-----AAGGA
	Mouse	CAGGTGCAATTCCTAAGCCAATCACAAGCACCTGTCTGACCCTATCTCCTAGTCCAGGA
		* * * * *
	Human	GGGAG
	Mouse	GCGGT
		* *


**Figure S2. Conservation of the *dACE2*-Ex1c sequences.**

**A).** Conservation of the 140 bp sequence of *dACE2*-Ex1c (human chrX:15,580,281-15,580,420, GRCh38/hg38) was analyzed by BLAT in 100 vertebrate species in the UCSC genome browser ([www.genome.ucsc.edu](http://www.genome.ucsc.edu)). The sequence is highly conserved in primates but is less conserved or absent in non-primates, precluding *dACE2* transcript initiation or translation into an ACE2-type protein. The long bar indicates the entire Ex1c (140 bp) and the short bar indicates the protein-coding part of this exon (30 bp), starting from the ATG codon indicated by an arrow and highlight; the gene direction is from right to left. **B).** Comparison between human and mouse sequences; \*- conserved bases; transcription start site (TSS) and translation start site (ATG) are indicated based on the human sequence. Human and mouse sequences share 43.7% identity within 500 bp (includes Ex1c, 5'UTR and promoter). Sequences were downloaded from UCSC genome browser and aligned using Clustal Omega.


**A****B**

**Figure S3. *ACE2* expression patterns in mouse and human lung cells infected with the respiratory syncytial virus (RSV).**

**A)** Sashimi plots of the *Ace2* region in a lung RNA-seq dataset from mice mock/RSV- infected (in triplicates). *Ace2*-Ex1a and Ex1b show similar expression patterns in all samples. The expression of *dACE2*-Ex1c is not observed, consistent with the absence of the corresponding genomic sequence in mice (**Figure 1D, Figure S1A, B**). **B)** Sashimi plots of the *ACE2* region in H292, a human lung mucoepidermoid pulmonary carcinoma cell line, show that expression of *ACE2* from Ex1a and Ex1b and *dACE2* from Ex1c is very low at baseline. Only *dACE2* expression is induced by RSV infection. Note: The mouse and human *ACE2* genes are shown in opposite orientations, as presented in the Integrative Genomic Viewer (IGV). Dataset: PRJNA588982.




**Figure S4. Expression of *ACE2* and *dACE2* in normal human tissues.** RNA-seq read counts for *ACE2-Ex1a* and *Ex1b* and *dACE2-Ex1c* in 27 human tissues. Dataset: PRJEB4337, n = 95



**Figure S5. *ACE2* expression in the Genotype-Tissue Expression (GTEx) project.**


Gene-based *ACE2* expression (combines *ACE2* and *dACE2* isoforms) in 17,382 normal human tissue samples of 54 tissue types in GTEx <https://www.gtexportal.org/home/gene/ACE2>.



**Figure S6. Expression of *ACE2* and *dACE2* in tumor-adjacent normal tissues in TCGA.**


Based on RNA-seq read counts, *ACE2*-Ex1b is detectable in multiple samples of several tissue types. *dACE2*-Ex1c expression is more restricted and most common in normal tissue adjacent to tumors of head and neck (HNSC), stomach (STAD), lung squamous carcinoma (LUSC), colon (COAD), and esophagus (ESCA).






**Figure S7. Expression of *ACE2* and *dACE2* across 10,185 tumors of 33 types in TCGA.**

Based on RNA-seq read counts, *ACE2*-Ex1b is most expressed in kidney tumors - kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP). Most samples expressing *dACE2*-Ex1c are squamous tumors of head and neck (HNSC) and the lungs (LUSC). Based on  $\geq 5$  reads/sample threshold, *ACE2*-Ex1a is expressed in 12.6%, *ACE2*-Ex1b – in 38.0% and *dACE2*-Ex1c - in 16.8% of all tumors.



**Figure S8. Analysis of *dACE2* and *ACE2* expression in relation to *IFNG* expression in TCGA tumors and *in vitro* IFN- $\gamma$  treatment.**

**A)** Expression levels of all *IFN* genes annotated in TCGA tumors (n = 10,185) were acquired from cBioPortal (<https://www.cbioportal.org/>); expression of *IFNL4* was not available. At RSEM  $\geq 1$ , only expression of *IFNG* is common (61% samples), with mean expression RSEM=19.8 compared to other *IFN* genes (mean expression RSEM  $\leq 1.3$ ). **B, C)** Pearson correlation coefficients (r) for *dACE2* and *ACE2* vs. *IFNG* expression across tumors. *dACE2* showed significant positive correlations ( $r \geq 0.2$ ) with *IFNG* in 8 tumor types, while *ACE2* showed mainly negative correlations and only one positive correlation in breast cancer ( $r = 0.15$ ). Expression values for *dACE2* and *ACE2* were based on log2 normalized exon read counts (Ex1b and Ex1c) and for *IFNG* - on RSEM values. **D)** Treatment of cell lines with IFN- $\gamma$  (2ng/ml, 48 hrs) induced expression of *dACE2* but not *ACE2* in T84 cells.




**Figure S9. Unsupervised self-organizing map (SOM) analysis in TCGA-LUSC tumors**

**A)** Construction of the unsupervised SOM of TCGA-LUSC tumors ( $n=501$ ) based on Z-scores calculated for each of the 270 curated ISGs. Each hexagon includes a mean of 5 (range 1-14)



tumors with similar ISG expression profiles. Colors denote clusters (1-6) of tumors with similar ISG expression profiles. **B)** Heatmap of the 6 SOM-defined clusters plotting the expression of top 100 ISGs selected by ranking of the initial set of 270 ISGs based on their contribution to these clusters. Cluster 5 includes 114 tumors with the highest ISG expression, whereas cluster 3 includes 72 tumors with the lowest ISG expression. **C)** Volcano plots showing FDR-adjusted p-values and Pearson correlation coefficients ( $r$ ) for expression of *dACE2* and *ACE2* in relation to expression of the top 100 ISGs within cluster 5. In total, *dACE2* was significantly (FDR p-value  $< 0.05$ ) correlated with expression of 20 ISGs and *ACE2* - with 5 ISGs.



**Figure S10. Peptides encoded by dACE2-Ex1c are detected by protein sequencing in tumors.**

**A)** Results of peptide query in PepQuery2 proteomics database of mass-spec data in 174 ovarian, 95 colon, and 105 breast tumors in TCGA (Wen et al., 2019). Three peptides – MREAGWDK, EAGWDKGGGR, and GGRILMCTK uniquely correspond to 10 aa encoded by *dACE2-Ex1c*. The latter peptide results from the splicing of *dACE2-Ex1c* with its downstream exon. The total number of identified peptides, the number of samples with specific peptides, and corresponding parameters for a peptide-spectrum match (PSM) are shown in table format. **B)** Representative spectra of two peptides matching with the protein encoded by *dACE2-Ex1c*. M/z refers to the mass by charge ratio. The b-series and y-series ions showed the correct mapping of residues in the query aa sequence.

## REFERENCES

- Fagerberg, L., Hallstrom, B.M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpour, S., Danielsson, A., Edlund, K., *et al.* (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics* *13*, 397-406.
- McAllister, C.S., Ansaldi, D., Growcott, E.J., Zhong, Y., Quackenbush, D., Wolff, K.C., Chen, Z., Tanaseichuk, O., Lelais, G., Barnes, S.W., *et al.* (2020). Dexamethasone inhibits respiratory syncytial virus-driven mucus production while increasing viral replication without altering antiviral interferon signaling. *Virology* *540*, 195-206.
- Santer, D.M., Minty, G.E.S., Golec, D.P., Lu, J., May, J., Namdar, A., Shah, J., Elahi, S., Proud, D., Joyce, M., *et al.* (2020). Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. *PLoS Pathog* *16*, e1008515.
- Stanifer, M.L., Kee, C., Cortese, M., Zumaran, C.M., Triana, S., Muenkner, M., Krausslich, H.G., Alexandrov, T., Bartenschlager, R., and Boulant, S. (2020). Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells. *Cell Rep*, 107863.
- Wen, B., Wang, X., and Zhang, B. (2019). PepQuery enables fast, accurate, and convenient proteomic validation of novel genomic alterations. *Genome Res* *29*, 485-493.